InflaRx (Nasdaq: IFRX) is a biopharmaceutical business in the late stages of clinical development with a focus on leveraging its unique technology to identify and create pioneering, potent, and selective C5a inhibitors. C5a, a component of the complement system, plays a significant role in the advancement of various autoimmune and inflammatory conditions. Founded in 2007, InflaRx operates from locations in Jena and Munich, Germany, and Ann Arbor, MI, USA.
Inflarx
Headquarters
Germany